{"id":6247,"date":"2025-07-11T14:47:55","date_gmt":"2025-07-11T14:47:55","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=poster&#038;p=6247"},"modified":"2025-10-15T06:35:46","modified_gmt":"2025-10-15T06:35:46","slug":"protectole-sparsentan-maximized-irbesartan-igan","status":"publish","type":"poster","link":"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protectole-sparsentan-maximized-irbesartan-igan\/","title":{"rendered":"Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial\u00a0"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header.png\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial\u00a0<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\n\n\r\n\t<section style=\"padding-top:0px;margin-top:calc(-180px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\t\t\t\t<div class=\"info-block-type\"><i class=\"icon2-journal\" aria-hidden=\"true\"><\/i> Poster<\/div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\" aria-hidden=\"true\"><\/i> Published on June 4, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics:<\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tContributors<br \/><span>Floege J, Rizk DV, Preciado P et al.<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tPresented at:<br \/><span>ERA 2025<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/ERA2025-Poster-PROTECT-OLE-Trial.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"btn btn-outline\">View poster<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-share\">\n\t\t\tShare: \n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotectole-sparsentan-maximized-irbesartan-igan%2F&#038;text=Effects+of+Sparsentan+after+Maximized+Angiotensin+Receptor+Blocker+%28ARB%29+Treatment+in+Patients+with+IgA+Nephropathy+%28IgAN%29+in+the+PROTECT+Trial%C2%A0\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotectole-sparsentan-maximized-irbesartan-igan%2F&#038;title=Effects+of+Sparsentan+after+Maximized+Angiotensin+Receptor+Blocker+%28ARB%29+Treatment+in+Patients+with+IgA+Nephropathy+%28IgAN%29+in+the+PROTECT+Trial%C2%A0\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotectole-sparsentan-maximized-irbesartan-igan%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Effects%20of%20Sparsentan%20after%20Maximized%20Angiotensin%20Receptor%20Blocker%20%28ARB%29%20Treatment%20in%20Patients%20with%20IgA%20Nephropathy%20%28IgAN%29%20in%20the%20PROTECT%20Trial%C2%A0&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotectole-sparsentan-maximized-irbesartan-igan%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-about-the-researc-h\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">About the researc<\/mark><\/span><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">h<\/mark><\/span><\/h2>\n\n\n\n<div class=\"pdf-block\">\n\t\t\t\t<iframe src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/ERA2025-Poster-PROTECT-OLE-Trial.pdf\" frameborder=\"0\"><\/iframe>\n\t\t<div class=\"pdf-block--buttons\">\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/ERA2025-Poster-PROTECT-OLE-Trial.pdf\" class=\"btn\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"View\">View<\/a>\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/ERA2025-Poster-PROTECT-OLE-Trial.pdf\" class=\"btn btn-outline\" download aria-label=\"Download\">Download<\/a>\n\t<\/div>\n<\/div>\n\n\n<h3 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-summary\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">Summary<\/mark><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-background\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Background<\/span><\/mark><\/h4>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>Sparsentan, a non-immunosuppressive, <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\" target=\"_blank\" rel=\"noreferrer noopener\">Dual Endothelin Angiotensin Receptor Antagonist (DEARA)<\/a><\/span><\/mark> is indicated to slow kidney function decline in adults with primary IgA nephropathy who are at risk for disease progression<sup>1-4<\/sup><\/li>\n\n\n\n<li>In the double-blind period of the <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protect-2-year-results-sparsentan-vs-irbesartan-iga-nephropathy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Phase 3 PROTECT trial<\/a><\/span><\/mark>, sparsentan showed superior proteinuria reduction and kidney function preservation, compared with the maximum labeled dose of irbesartan<sup>1,5<\/sup><\/li>\n\n\n\n<li>In the PROTECT Open Label Extension (OLE), eligible participants could receive up to 156 weeks of sparsentan, regardless of treatment arm in the double-blind period<sup>1<\/sup><\/li>\n<\/ul>\n<\/div>\n\n\n<h5 class=\"wp-block-heading\" id=\"h-aim\"><br><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Aim<\/span><\/mark><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This analysis of the PROTECT OLE reported the safety and efficacy of sparsentan up to 48 weeks in patients who initiated sparsentan after receiving maximum labeled dose irbesartan for 110 weeks during the double-blind period<sup>1<\/sup><\/p>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-approach\"><br><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Approach<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>To be eligible for the PROTECT OLE, participants had to complete 110 weeks of randomized study treatment and have an estimated glomerular filtration rate (eGFR) &gt;20 mL\/min\/1.73 m<sup>2<\/sup> at Week 110<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-key-findings\"><br><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Key findings<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In PROTECT OLE period (n=128), sparsentan demonstrated<sup>1<\/sup>:<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>A rapid reduction in urine protein-creatinine ratio (UPCR) that was sustained for up to 48 weeks<sup>1<\/sup><div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>Mean UPCR was reduced from 1.2 g\/g at Week 0 (95% confidence interval [CI]: 1.0-1.4) to 0.6 g\/g at Week 48 (95% CI: 0.5-0.7)<\/li>\n<\/ul>\n<\/div><\/li>\n\n\n\n<li>Stable eGFR values and well-controlled BP for up to 48 weeks<sup>1<\/sup><\/li>\n<\/ul>\n<\/div>\n\n\n<p>In the PROTECT OLE period, adverse event (AE) rates were low with no new safety signals<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-conclusions\"><br><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Conclusions<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>In PROTECT, patients with IgA nephropathy who previously received maximum labeled dose irbesartan for 2 years, experienced rapid and sustained proteinuria reductions after initiating sparsentan in the OLE period<sup>1<\/sup><\/li>\n\n\n\n<li>Sparsentan was generally well tolerated, and no new safety signals were seen<sup>1<\/sup><\/li>\n<\/ul>\n<\/div>\n\n\n<p><br><br><br><br><\/p>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong>\u00a0to receive scientific updates<br \/>\nfor healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/poster\/6247#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center\" id=\"h-related-c-ontent\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">Related <\/mark><\/span><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">c<\/mark><\/span><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">ontent<\/mark><\/span><\/h4>\n\n\n  <div class=\"carousel-posts poster-carousel swiper carousel-type-poster wp-block-grizzly-posts-carousel\">\n    <div class=\"swiper-wrapper\">\n      <div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/sparsentan-sglt2i-iga-nephropathy-protect-ole\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2025\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protect-proteinuria-remission-egfr\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protect-subgroup-analysis-proteinuria\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div>    <\/div>\n    <div class=\"swiper-pagination\"><\/div>\n          <\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-footnotes\" style=\"margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Footnotes<\/mark><\/span><\/h5>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\">BP, blood pressure; CI, confidence interval; DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; IgAN, IgA nephropathy; OLE, open label extension; UPCR, urine protein-creatinine ratio.&nbsp;<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Floege J et al. Poster presented at: European Renal Association 2025; June 4-7, 2025; Vienna, Austria.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kohan DE et al. <em>Clin Sci (Lond)<\/em>. 2024;138(11):645-662.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H et al. <em>Expert Rev Clin Immunol<\/em>. 2024;20(6):571-576.<\/li>\n\n\n\n<li class=\"has-small-font-size\">FILSPARI\u00ae (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9\/2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet<\/em>. 2023;402(10417):2077-2090.&nbsp;<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\"><br>MA-SP-25-0101 | July 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":4590,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":"","pdf_file_link":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/ERA2025-Poster-PROTECT-OLE-Trial.pdf"},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[175],"study_type":[176],"resource_type":[199,180],"class_list":["post-6247","poster","type-poster","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-protect","study_type-clinical","resource_type-poster","resource_type-summary"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PROTECT Open Label Extension (OLE): Sparsentan After Maximized ARB Use<\/title>\n<meta name=\"description\" content=\"Learn about the efficacy and safety of sparsentan after maximized ARB treatment in patients with IgAN. Read about the PROTECT OLE now.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial\u00a0\" \/>\n<meta property=\"og:description\" content=\"Learn about the efficacy and safety of sparsentan after maximized ARB treatment in patients with IgAN. Read about the PROTECT OLE now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T06:35:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/\",\"name\":\"PROTECT Open Label Extension (OLE): Sparsentan After Maximized ARB Use\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/PROTECT-surrogate-efficacy-endpoints_header.png\",\"datePublished\":\"2025-07-11T14:47:55+00:00\",\"dateModified\":\"2025-10-15T06:35:46+00:00\",\"description\":\"Learn about the efficacy and safety of sparsentan after maximized ARB treatment in patients with IgAN. Read about the PROTECT OLE now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/PROTECT-surrogate-efficacy-endpoints_header.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/PROTECT-surrogate-efficacy-endpoints_header.png\",\"width\":1920,\"height\":1080,\"caption\":\"Decorative image\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protectole-sparsentan-maximized-irbesartan-igan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PROTECT OLE: Effect of Sparsentan After ARB Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PROTECT Open Label Extension (OLE): Sparsentan After Maximized ARB Use","description":"Learn about the efficacy and safety of sparsentan after maximized ARB treatment in patients with IgAN. Read about the PROTECT OLE now.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial\u00a0","og_description":"Learn about the efficacy and safety of sparsentan after maximized ARB treatment in patients with IgAN. Read about the PROTECT OLE now.","og_url":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-15T06:35:46+00:00","twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/","url":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/","name":"PROTECT Open Label Extension (OLE): Sparsentan After Maximized ARB Use","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header.png","datePublished":"2025-07-11T14:47:55+00:00","dateModified":"2025-10-15T06:35:46+00:00","description":"Learn about the efficacy and safety of sparsentan after maximized ARB treatment in patients with IgAN. Read about the PROTECT OLE now.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2019\/10\/PROTECT-surrogate-efficacy-endpoints_header.png","width":1920,"height":1080,"caption":"Decorative image"},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protectole-sparsentan-maximized-irbesartan-igan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"PROTECT OLE: Effect of Sparsentan After ARB Use"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 13:11:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"product","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster\/6247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/poster"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/4590"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=6247"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=6247"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=6247"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=6247"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=6247"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=6247"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=6247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}